Format

Send to

Choose Destination
Curr Opin Infect Dis. 2009 Apr;22(2):154-8. doi: 10.1097/QCO.0b013e328322a006.

Aerosolized antibiotics to treat ventilator-associated pneumonia.

Author information

1
Service de Réanimation Médicale, Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, Paris Cedex 13, France. charles-edouard.luyt@psl.aphp.fr

Abstract

PURPOSE OF REVIEW:

This review summarizes the recent data on antibiotic aerosolization to treat ventilator-associated pneumonia.

RECENT FINDINGS:

Most studies on antibiotic aerosolization have been case reports or descriptive studies. The results of a recent randomized, placebo-controlled trial indicated that adjunctive use of nebulized antibiotic with intravenous antibiotics to treat purulent tracheobronchitis was associated with a better outcome than placebo aerosolization. A randomized study, so far published only as an abstract, showed that amikacin aerosolized with a vibrating-mesh nebulizer--a new-generation device--was well distributed in the lung parenchyma and might lead to less intravenous antibiotic use. Several thorough reviews on nebulization devices, techniques and drawbacks have been published recently.

SUMMARY:

Despite recent promising findings, the widespread use of aerosolized antibiotics to treat ventilator-associated pneumonia cannot be recommended. It should be restricted to the treatment of multidrug-resistant Gram-negative ventilator-associated pneumonia.

PMID:
19276883
DOI:
10.1097/QCO.0b013e328322a006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center